Altimmune Inc reports results for the quarter ended March 31 - Earnings Summary

Altimmune

13/05/2025 14:32

Altimmune Inc ALT.OQ reported a quarterly adjusted loss of 26 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -34 cents.  The mean expectation of seven analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -40 cents to -33 cents per share.

Revenue held steady 0% to $5.00 thousand from a year ago; analysts expected zero.

Altimmune Inc's reported EPS for the quarter was a loss of 26 cents​.

The company reported a quarterly loss of $19.58 million.

Altimmune Inc shares had risen by 20.2% this quarter and lost 16.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 3.9% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Altimmune Inc is $25.00

This summary was machine generated from LSEG data May 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.36
-0.26
Beat
Dec. 31 2024
-0.33
-0.33
Met
Sep. 30 2024
-0.35
-0.32
Beat
Jun. 30 2024
-0.34
-0.35
Missed